HOME > BUSINESS
BUSINESS
- Astellas Seeks US Approval for Additional Indication of Enzalutamide
March 20, 2014
- Astellas, Daiichi Sankyo Hook Up in Compound Library Sharing
March 20, 2014
- Galderma Files NDA for Cancer Odor Treatment
March 20, 2014
- Eli Lilly Japan Sales Up 9% in 2013
March 19, 2014
- Sanofi Settles Allegra Generic Suit with Elmed Eisai, Kobayashi Kako
March 19, 2014
- Daiichi Sankyo Files NDA for Methylene Blue for Methemoglobinemia
March 19, 2014
- Genzyme Asia Pacific Senior VP to Run Japan Operations
March 18, 2014
- Novartis Workers were Acting for Office of SIGN Trial Initiator Group: University of Tokyo
March 17, 2014
- Bayer Yakuhin Chairman Eiki to Step Down
March 17, 2014
- LEO Pharma to Carefully Ponder When to Begin Solo Marketing in Japan: Local Head
March 14, 2014
- Nichi-Iko to Name Company Succeeded from Astellas “Nichi-Iko Pharma Tech”
March 14, 2014
- Takeda to Abolish CCO Post, Commercial Operations to Come Directly Under Weber’s Control
March 14, 2014
- Will Original Drug Makers Suddenly Embrace AGs? Comments of MHLW Official Could Spark Big Changes
March 14, 2014
- Otsuka to Disclose Patient-Level Clinical Trial Data
March 13, 2014
- Santen to Create New Exec Posts to Accelerate Globalization
March 13, 2014
- Novartis Japan Sales Tick Up 0.8%, Diovan Down 13%, Tasigna Up 35%
March 13, 2014
- Torii Confirms Positive Results from PII/III Study of Investigational Allergen Immunotherapy Treatment TO-203
March 13, 2014
- AstraZeneca, Osaka University Aim to Resurrect Ditched Drug Candidates
March 13, 2014
- 19 Pharmacy-Operating Companies Join Bidding Group for Drug Purchasing
March 12, 2014
- Announcement: 7th Annual Marketing Excellence Japan 2014 – Westin Tokyo, May 13 – 14
March 12, 2014
ページ
I recently attended a fantastic conference hosted by Prospection Japan, and one speaker, Dr. Joe Ledsam, really blew me away with his insights. He shared some truly fascinating developments about how AI is set to revolutionize healthcare, from how doctors…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…